// Workers AI · dad joke modeWhat did Pralurbactam say? It's an act-am.

Pralurbactam
Clinical data
Other names	FL058
Legal status
Legal status	investigational;
Identifiers
	IUPAC name [(2S,5R)-2-[2-(diaminomethylideneamino)oxyethoxycarbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate;
CAS Number	2163782-59-8;
PubChem CID	155048066;
IUPHAR/BPS	13037;
DrugBank	DB19437;
ChemSpider	128921637;
UNII	GTP46AY74R;
ChEBI	CHEBI:759183;
ChEMBL	ChEMBL5314477;
Chemical and physical data
Formula	C10H18N6O8S
Molar mass	382.35 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCON=C(N)N;
	InChI InChI=InChI=1S/C10H18N6O8S/c11-9(12)14-23-4-3-22-13-8(17)7-2-1-6-5-15(7)10(18)16(6)24-25(19,20)21/h6-7H,1-5H2,(H,13,17)(H4,11,12,14)(H,19,20,21)/t6-,7+/m1/s1; Key:HOJIPBUGHMYVQD-RQJHMYQMSA-N;

Pralurbactam is an investigational new drug that is being evaluated by Qilu Pharmaceutical for the treatment of hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP). It is a DBO class β-lactamase inhibitor that is co-administered with β-lactam antibiotics to overcome bacterial resistance to the later.^[1]^[2]^[3]

Clinical trials

Pralurbactam is in phase 3 clinical trials for HAP and VAP.^[4]

↑ "Pralurbactam - Qilu Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
↑ Tan Z, Lin Y, Fan J, Jia Y, Zheng S, Wang X, et al. (February 2025). "FL058, a novel β-lactamase inhibitor, increases the anti-Mycobacterium abscessus activity of imipenem". International Journal of Antimicrobial Agents. 65 (2) 107414. doi:10.1016/j.ijantimicag.2024.107414. PMID 39710142.
↑ Karaiskos I, Gkoufa A, Kyriazopoulou E, Polyzou E, Rapti V, Ioannidis K, et al. (June 2026). "An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens". Expert Opinion on Drug Metabolism & Toxicology: 1–40. doi:10.1080/17425255.2026.2691051. PMID 42317028.
↑ Clinical trial number NCT07327619 for "A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.